Replies to post #212538 on Biotech Values

[goodJohnhunting]

BCLI get's 16M Non-dilutive funding for ALS NurOwn Phase III study.

http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2287895

All the best,
John

[DewDiligence]

VNDA tries to hide phase-2 failure in pruritis:

https://finance.yahoo.com/news/vandas-tradipitant-improves-itch-disease-200400031.html

Tradipitant demonstrated significant and clinically meaningful improvement in a number of measures of itch. Specifically, significant improvements were observed in the measurement of Worst Itch Visual Analog Scale (VAS) (p=0.019). Tradipitant also showed significant effects in a responder analysis for Worst Itch in patients who achieved improvements of greater than or equal to 40 points improvement from baseline in Worst Itch VAS scores (p=0.037) or greater than or equal to 30 points (p=0.049). [Oh, by the way…] On the pre-specified primary endpoint of Average Itch VAS, tradipitant showed improvement over placebo, but this improvement was not significant due to high placebo effect and the lack of sensitivity of this measure.

That paragraph is halfway into the PR, LOL.